+39 02 610346.1 - info@newron.com

Success in CNS drug development – Innovation in Rare Diseases

We are a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Our shares are listed on the SIX Swiss Exchange (NWRN).

Latest press releases

  • 16Jan
    Zambon together with Valeo Pharma announce the approval of Onstryv® (safinamide) for PD in Canada

  • 30Nov
    Zambon announces approval and ARTG listing of safinamide in Australia for treatment of patients with Parkinson’s disease

     

  • 31Oct
    Newron Pharmaceuticals hosts its 2018 R&D Day in New York City

  • 30Oct
    Investment Plan for Europe: EIB backs Italian CNS drug developer Newron Pharmaceuticals with up to EUR 40m

     

  • 23Oct
    Meiji Seika and Eisai announce submission of manufacturing and marketing approval application in Japan for safinamide in Parkinson’s disease

  • 15Oct
    Newron Pharmaceuticals Announces Prominent Medical Experts to Present at its 2018 R&D Day on October 31 in New York

     

View All

Newron share price

Events

  • 27Feb
    2019 Leerink Partners Gloal Healthcare Conference

    February 27 - March 1, 2019 - Lotte New York Palace Hotel, New York, USA

  • 11Feb
    BIO CEO & Investor Conference 2019

    February 11-12, 2019 - Marriott Marquis, New York, NY, USA

  • 7Jan
    J.P. Morgan 37th Annual Healthcare Conference 2019

    January 7-10, 2019 - San Francisco, CA, USA

View Event Calendar